Change from baseline (%) in body weight during Study 3 Effect of SAXENDA on Body Weight in a 160-week Trial (Study 1, Subset of Patients with Abnormal Blood Glucose at Randomization) The numbers and percentages of patients known to have lost greater than or equal to 5% body weight at Week 56 and/or Week 160 in Study 1 (patients with abnormal glucose at randomization only) are summarized in Table 5 for descriptive purposes
More and more people are experiencing the benefits of these medications, with one out of eight adults, or 12%, in the United States reporting having taken a GLP-1 drug in a 2024 survey, said Roosevelt Allen, DDS, MAGD, ABGD, chief dental officer, United Concordia Dental
That broader availability though still limited may be what's driving GLP-1 usage higher overall
16,17 Exenatide, a GLP-1 RA, shows significant promise for treating IIH by rapidly reducing intracranial pressure
If exposed to: Heat Direct sunlight Unstable temperatures it may impact how the medication performs in your body
Higher monthly cost than entry-level TRT